According to Vision Research Reports, the allergy-relieving eye drops market size is expected to reach US$ 1,960 million by 2027 and expanding at a CAGR of 5.2% from 2020 to 2027.
Rise in number of geriatric patients, increase in awareness regarding minor eye disorders, and high unmet medical needs are expected to augment the global market from 2018 to 2026. The allergy-relieving eye drops market is projected to expand owing to an increase in the prevalence of eye-related disorders among the population, demand for better treatments, and development of healthcare infrastructure in various economies.
Increasing geriatric population and rising awareness regarding eye diseases
According to data published by United Nations Department of Economics and Social Affairs, the global geriatric population is expected to double by the end of 2050 and is projected to reach nearly 2.1 billion. This increasing geriatric population is prone to significant risk of eye-related disorders, including blindness. Public awareness regarding common eye conditions is increasing in developing countries, leading to early diagnosis and treatment of eye diseases. Furthermore, a large number of organizations are dedicated to fight blindness, restore vision, and create awareness regarding eye health. National Eye Institute, National Association for Visually Handicapped, National Federation of the Blind, and Prevent Blindness are a few eye health organizations concerned with the prevention of eye diseases.
Increase in prevalence and incidence rates of eye-related disorders
According to World Health Organization (WHO), there are 285 million visually impaired people globally, approximately 90% of them living in low to middle income countries. Furthermore, approximately 95 million people suffer from cataract and 20 million suffer from various eye conditions, including glaucoma, muscular degeneration, infections, and childhood-related conditions. Significant rise in incidence of eye-related diseases, especially in developed countries, is anticipated to drive the allergy-relieving eye drops market between 2018 and 2026.
Patients undergoing open angle glaucoma and AMD in the U.S., were 2.7 Mn and 2.1 Mn, respectively. This number is projected to increase to 3.3 Mn and 2.5 Mn, respectively, by 2020. Increasing patient pool in developing countries as well as developed countries is estimated to propel healthcare spending for eye treatments in these countries and drive the allergy-relieving eye drops market.
High unmet needs in patients with ocular allergy
The currently available treatment options are insufficient, as almost 30% to 40% of patients suffer from persistent allergic inflammation due to incomplete response to antihistamines. Therefore, a large proportion of patients with ocular allergy have high unmet needs, providing an opportunity for the development of novel treatment for eye-related allergies. According to an article published in NCBI, approximately 20% of the total population suffers from some form of allergic conjunctivitis and significant proportion of patients experience chronic allergy due to low response to existing therapies.
Antihistamines segment dominates the global market due to its choice as first line of treatment for allergic conjunctivitis
In terms of drug class, antihistamines was a highly attractive segment of the global allergy-relieving eye drops market, followed by non-steroidal anti-inflammatory drugs and vasoconstrictors segments. This is attributable to the preference for antihistamines as the first line of treatment for allergic conjunctivitis. According to a study published by NCBI, dual-acting antihistamines combined with mast cell stabilizers are considered the first-line therapeutics for allergic conjunctivitis, as they provide acute relief against signs and symptoms and block persistent inflammation to promote regression of ocular allergy. Moreover, they are well-tolerated for chronic usage in case of persistent ocular allergies.
North America dominates the global market owing to significant funding from government in order to improve quality of life for persons suffering from Alzheimer’s disease
North America dominates the overall allergy-relieving eye drops market due to a large patient pool, high cost of specialty branded drugs, and increasing patient pool. The region is estimated to maintain its dominance of the global market during the forecast period. According to an article published by The Journal of Allergy and Clinical Immunology, up to 40% of the U.S. population experiences ocular allergy at least once in their lifetime. Moreover, rising healthcare expenditure and increasing investments are key factors that are anticipated to boost the allergy-relieving eye drops market in the next few years. The allergy-relieving eye drops market in Asia Pacific is projected to expand at a notable CAGR due to increasing awareness regarding allergy-relieving eye drops in developing countries and government initiatives introduced in the region.
Investments by key players is driving the global allergy-relieving eye drops market.
Key players dominating the allergy-relieving eye drops market include Allergan Plc., Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.
The report analyzes and forecasts the allergy-relieving eye drops market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of allergy-relieving eye drops, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major allergy-relieving eye drops companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of allergy-relieving eye drops upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of allergy-relieving eye drops and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global allergy-relieving eye drops market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the allergy-relieving eye drops market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of allergy-relieving eye drops market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in the Report
The report also profiles major players operating in the global allergy-relieving eye drops market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Allergan Plc., Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., and Santen Pharmaceutical Co., Ltd.
The global allergy-relieving eye drops market has been segmented as below:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allergy-relieving Eye Drops Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Allergy-relieving Eye Drops Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
5.2. Pipeline Analysis
5.3. Regulatory Scenario by Region
6. Global Allergy-relieving Eye Drops Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Antihistamines
6.3.2. Non-steroidal Anti-inflammatory Drugs
6.3.3. Vasoconstrictors
6.3.4. Others
6.4. Global Allergy-relieving Eye Drops Market Attractiveness, by Drug Class
7. Global Allergy-relieving Eye Drops Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
7.3.1. Seasonal and Perennial Allergic Conjunctivitis
7.3.2. Vernal Keratoconjunctivitis
7.3.3. Atopic Keratoconjunctivitis
7.3.4. Giant Papillary Conjunctivitis
7.3.5. Others
7.4. Global Allergy-relieving Eye Drops Market Attractiveness, by Type
8. Global Allergy-relieving Eye Drops Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital Pharmacies
8.3.2. Retail
8.3.3. Online Sales
8.4. Global Allergy-relieving Eye Drops Market Attractiveness, by Distribution Channel
9. Global Allergy-relieving Eye Drops Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Allergy-relieving Eye Drops Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Allergy-relieving Eye Drops Market Attractiveness, by Country/Region
10. North America Allergy-relieving Eye Drops Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Antihistamines
10.2.2. Non-steroidal Anti-inflammatory Drugs
10.2.3. Vasoconstrictors
10.2.4. Others
10.3. North America Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
10.3.1. Seasonal and Perennial Allergic Conjunctivitis
10.3.2. Vernal Keratoconjunctivitis
10.3.3. Atopic Keratoconjunctivitis
10.3.4. Giant Papillary Conjunctivitis
10.3.5. Others
10.4. North America Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail
10.4.3. Online Sales
10.5. North America Allergy-relieving Eye Drops Market Value Forecast, by Country, 2016–2026
10.5.1. US
10.5.2. Canada
10.6. North America Allergy-relieving Eye Drops Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Allergy-relieving Eye Drops Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Antihistamines
11.2.2. Non-steroidal Anti-inflammatory Drugs
11.2.3. Vasoconstrictors
11.2.4. Others
11.3. Europe Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
11.3.1. Seasonal and Perennial Allergic Conjunctivitis
11.3.2. Vernal Keratoconjunctivitis
11.3.3. Atopic Keratoconjunctivitis
11.3.4. Giant Papillary Conjunctivitis
11.3.5. Others
11.4. Europe Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail
11.4.3. Online Sales
11.5. Europe Allergy-relieving Eye Drops Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. France
11.5.3. U.K.
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Allergy-relieving Eye Drops Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Allergy-relieving Eye Drops Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Antihistamines
12.2.2. Non-steroidal Anti-inflammatory Drugs
12.2.3. Vasoconstrictors
12.2.4. Others
12.3. Asia Pacific Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
12.3.1. Seasonal and Perennial Allergic Conjunctivitis
12.3.2. Vernal Keratoconjunctivitis
12.3.3. Atopic Keratoconjunctivitis
12.3.4. Giant Papillary Conjunctivitis
12.3.5. Others
12.4. Asia Pacific Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail
12.4.3. Online Sales
12.5. Asia Pacific Allergy-relieving Eye Drops Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Allergy-relieving Eye Drops Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Allergy-relieving Eye Drops Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Antihistamines
13.2.2. Non-steroidal Anti-inflammatory Drugs
13.2.3. Vasoconstrictors
13.2.4. Others
13.3. Latin America Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
13.3.1. Seasonal and Perennial Allergic Conjunctivitis
13.3.2. Vernal Keratoconjunctivitis
13.3.3. Atopic Keratoconjunctivitis
13.3.4. Giant Papillary Conjunctivitis
13.3.5. Others
13.4. Latin America Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail
13.4.3. Online Sales
13.5. Latin America Allergy-relieving Eye Drops Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Allergy-relieving Eye Drops Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Allergy-relieving Eye Drops Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Allergy-relieving Eye Drops Market Value Forecast, by Drug Class, 2016–2026
14.2.1. Antihistamines
14.2.2. Non-steroidal Anti-inflammatory Drugs
14.2.3. Vasoconstrictors
14.2.4. Others
14.3. Middle East & Africa Allergy-relieving Eye Drops Market Value Forecast, by Type, 2016–2026
14.3.1. Seasonal and Perennial Allergic Conjunctivitis
14.3.2. Vernal Keratoconjunctivitis
14.3.3. Atopic Keratoconjunctivitis
14.3.4. Giant Papillary Conjunctivitis
14.3.5. Others
14.4. Middle East & Africa Allergy-relieving Eye Drops Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail
14.4.3. Online Sales
14.5. Middle East & Africa Allergy-relieving Eye Drops Market Value Forecast, by Country/Sub-region 2016–2026
14.5.1. GCC Countries
14.5.2. Israel
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. Middle East & Africa Allergy-relieving Eye Drops Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Allergy-relieving Eye Drops Market Share Analysis, by Company (2016)
15.2. Company Profiles
15.2.1. Allergan plc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Financial Overview
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Financial Overview
15.2.2.5. Strategic Overview
15.2.3. Johnson & Johnson Services, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Financial Overview
15.2.3.5. Strategic Overview
15.2.4. Pfizer, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Financial Overview
15.2.4.5. Strategic Overview
15.2.5. F. Hoffmann-La Roche Ltd.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Financial Overview
15.2.5.5. Strategic Overview
15.2.6. Bausch Health Companies Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Financial Overview
15.2.6.5. Strategic Overview
15.2.7. Regeneron Pharmaceuticals, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Financial Overview
15.2.7.5. Strategic Overview
15.2.8. Santen Pharmaceutical Co., Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Financial Overview
15.2.8.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers